{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000099","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.200894+00:00","generated_at":"2026-06-14T18:31:14.800561+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Centessa receives FDA Fast Track for SerpinPC in hemophilia B","bullets":["FDA granted Fast Track designation to SerpinPC, an investigational inhibitor of activated protein C.","SerpinPC is being developed for hemophilia B, with or without inhibitors.","Fast Track may enable expedited development and rolling review; CEO cites potential first-in-class subcutaneous therapy.","Centessa continues to advance PRESent registrational studies for SerpinPC."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000099","json":"https://secwatch.observer/filing/0001847903-23-000099.json","markdown":"https://secwatch.observer/filing/0001847903-23-000099.md","text":"https://secwatch.observer/filing/0001847903-23-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000099/0001847903-23-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000099/cnta-20230522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:31:14.800561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}